Floatz logo

NY-ESO-1b

Melanoma (Skin)

Mayo ClinicEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Melanoma (Skin) cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

NY-ESO-1b is also rated in:

melanomaDormant
B
Indicative ·
58 / 100
View asset →
Metastatic MelanomaDormant
CCC
Indicative ·
51 / 100
View asset →
Advanced MalignanciesDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →